42 related articles for article (PubMed ID: 13679386)
1. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization.
Haicheur N; Benchetrit F; Amessou M; Leclerc C; Falguières T; Fayolle C; Bismuth E; Fridman WH; Johannes L; Tartour E
Int Immunol; 2003 Oct; 15(10):1161-71. PubMed ID: 13679386
[TBL] [Abstract][Full Text] [Related]
2. The translocation motif of hepatitis B virus improves protein vaccination.
Bleifuss E; Kammertoens T; Hutloff A; Quarcoo D; Dorner M; Straub P; Uckert W; Hildt E
Cell Mol Life Sci; 2006 Mar; 63(5):627-35. PubMed ID: 16482397
[TBL] [Abstract][Full Text] [Related]
3. In vivo assembly of epitope-coated biopolymer particles that induce anti-tumor responses.
Jenika D; Pounraj S; Wibowo D; Flaxl LM; Rehm BHA; Mintern JD
NPJ Vaccines; 2024 Jan; 9(1):18. PubMed ID: 38263169
[TBL] [Abstract][Full Text] [Related]
4. Designing and Analyzing the Structure of DT-STXB Fusion Protein as an Anti-tumor Agent: An
Mohseni Moghadam Z; Halabian R; Sedighian H; Behzadi E; Amani J; Imani Fooladi AA
Iran J Pathol; 2019; 14(4):305-312. PubMed ID: 31754360
[TBL] [Abstract][Full Text] [Related]
5. A synthetic delivery vector for mucosal vaccination.
Billet A; Hadjerci J; Tran T; Kessler P; Ulmer J; Mourier G; Ghazarian M; Gonzalez A; Thai R; Urquia P; Van Baelen AC; Meola A; Fernandez I; Deville-Foillard S; MacDonald E; Paolini L; Schmidt F; Rey FA; Kay MS; Tartour E; Servent D; Johannes L
Biomaterials; 2023 Nov; 302():122298. PubMed ID: 37713762
[TBL] [Abstract][Full Text] [Related]
6. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
[TBL] [Abstract][Full Text] [Related]
7. Engineered Synthetic STxB for Enhanced Cytosolic Delivery.
Hadjerci J; Billet A; Kessler P; Mourier G; Ghazarian M; Gonzalez A; Wunder C; Mabrouk N; Tartour E; Servent D; Johannes L
Cells; 2023 Apr; 12(9):. PubMed ID: 37174690
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.
Ruschig M; Marschall ALJ
BioDrugs; 2023 Mar; 37(2):181-203. PubMed ID: 36729328
[TBL] [Abstract][Full Text] [Related]
9. STxB as an Antigen Delivery Tool for Mucosal Vaccination.
Tartour E; Johannes L
Toxins (Basel); 2022 Mar; 14(3):. PubMed ID: 35324699
[TBL] [Abstract][Full Text] [Related]
10. Shiga Toxins: An Update on Host Factors and Biomedical Applications.
Liu Y; Tian S; Thaker H; Dong M
Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33803852
[TBL] [Abstract][Full Text] [Related]
11. Molecular Biology of
Menge C
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32456125
[TBL] [Abstract][Full Text] [Related]
12. Cellular and Mucosal Immune Responses Following Vaccination with Inactivated Mutant of Escherichia coli O157:H7.
Schaut RG; Boggiatto PM; Loving CL; Sharma VK
Sci Rep; 2019 Apr; 9(1):6401. PubMed ID: 31024031
[TBL] [Abstract][Full Text] [Related]
13. Prevention and Inhibition of TC-1 Cell Growth in Tumor Bearing Mice by HPV16 E7 Protein in Fusion with Shiga Toxin B-Subunit from shigella dysenteriae.
Sadraeian M; Khoshnood Mansoorkhani MJ; Mohkam M; Rasoul-Amini S; Hesaraki M; Ghasemi Y
Cell J; 2013; 15(2):176-81. PubMed ID: 23862120
[TBL] [Abstract][Full Text] [Related]
14. Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors.
Sandoval F; Terme M; Nizard M; Badoual C; Bureau MF; Freyburger L; Clement O; Marcheteau E; Gey A; Fraisse G; Bouguin C; Merillon N; Dransart E; Tran T; Quintin-Colonna F; Autret G; Thiebaud M; Suleman M; Riffault S; Wu TC; Launay O; Danel C; Taieb J; Richardson J; Zitvogel L; Fridman WH; Johannes L; Tartour E
Sci Transl Med; 2013 Feb; 5(172):172ra20. PubMed ID: 23408053
[TBL] [Abstract][Full Text] [Related]
15. Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.
Sadraeian M; Ghoshoon MB; Mohkam M; Karimi Z; Rasoul-Amini S; Ghasemi Y
Virol Sin; 2013 Feb; 28(1):43-8. PubMed ID: 23329470
[TBL] [Abstract][Full Text] [Related]
16. Adjuvants for allergy vaccines.
Moingeon P
Hum Vaccin Immunother; 2012 Oct; 8(10):1492-8. PubMed ID: 23095872
[TBL] [Abstract][Full Text] [Related]
17. The design of new adjuvants for mucosal immunity to Neisseria meningitidis B in nasally primed neonatal mice for adult immune response.
Ferreira T; De Gaspari E
ScientificWorldJournal; 2012; 2012():292073. PubMed ID: 22545012
[TBL] [Abstract][Full Text] [Related]
18. AB toxins: a paradigm switch from deadly to desirable.
Odumosu O; Nicholas D; Yano H; Langridge W
Toxins (Basel); 2010 Jul; 2(7):1612-45. PubMed ID: 22069653
[TBL] [Abstract][Full Text] [Related]
19. Shiga toxins induce autophagy leading to differential signalling pathways in toxin-sensitive and toxin-resistant human cells.
Lee MS; Cherla RP; Jenson MH; Leyva-Illades D; Martinez-Moczygemba M; Tesh VL
Cell Microbiol; 2011 Oct; 13(10):1479-96. PubMed ID: 21722286
[TBL] [Abstract][Full Text] [Related]
20. Controlling subcellular delivery to optimize therapeutic effect.
Mossalam M; Dixon AS; Lim CS
Ther Deliv; 2010 Jul; 1(1):169-93. PubMed ID: 21113240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
